HEMSAMIC 500MG | TRANEXAMIC | BLEEDING – 20 TABS
Tranexamic acid is an antifibrinolytic drug that inhibits breakdown of fibrin clots. It acts primarily by blocking the binding of plasminogen and plasmin to fibrin; direct inhibition of plasmin occurs only to a limited degree. Tranexamic acid is therefore used in Kenya in the treatment and prophylaxis of haemorrhage associated with excessive fibrinolysis, this includes excessive menstrual flow. It is also used in the prophylaxis of hereditary angioedema.
For short-term treatment, oral doses are 1g (or 15 to 25 mg/kg) 2 to 4 times daily are recommended.
Tranexamic acid appears to be well tolerated. It can however produce dose-related mild gastrointestinal disturbances. Tranexamic acid should not be used in patients with active intravascular clotting because of the risk of thrombosis. Patients with a predisposition to thrombosis are also at risk if given antifibrinolytic therapy.